Area of research
Molecular Biology · Oncology
Research interest
Research focused on Cancer research and T790M, with related work in Placebo, KRAS, Randomized controlled trial. Notable publications include 'A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia', 'Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance', and 'G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin'.
Oncogenic KRAS Induces Arginine Auxotrophy and Confers a Therapeutic Vulnerability to SLC7A1 Inhibition in Non–Small Cell Lung Cancer
Low‐Dose Chemotherapy Preferentially Shapes the Ileal Microbiome and Augments the Response to Immune Checkpoint Blockade by Activating AIM2 Inflammasome in Ileal Epithelial Cells
Lasiokaurin Regulates PLK1 to Induce Breast Cancer Cell G2/M Phase Block and Apoptosis
Arnicolide C Suppresses Tumor Progression by Targeting 14-3-3θ in Breast Cancer
Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations
<sup>18</sup>F-FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia
LS‐106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia
Sepiapterin reductase promotes hepatocellular carcinoma progression via FoxO3a/Bim signaling in a nonenzymatic manner
SNORD89 promotes stemness phenotype of ovarian cancer cells by regulating Notch1-c-Myc pathway
Identification of a new inhibitor of KRAS‐PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer
Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton’s tyrosine kinase inhibitors
Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity
G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin
Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma
Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors